DL-4-chlorophenylalanine t-butyl ester | 81085-20-3

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: DL-4-chlorophenylalanine t-butyl ester
• 英文别名: tert-butyl (2S)-2-amino-3-(4-chlorophenyl)propanoate
• CAS: 81085-20-3
• 化学式: C₁₃H₁₈ClNO₂
• 分子量: 255.744
• InChiKey: ORIUKBBWEBMOBM-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  DL-4-chlorophenylalanine t-butyl ester 在 TEA 、 1-羟基苯并三唑 、 苯甲醚 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 AcFTLDAD-(p-Cl)Phe
  参考文献：
  名称：

  Toward a Rational Design of Peptide Inhibitors of Ribonucleotide Reductase:  Structure−Function and Modeling Studies

  摘要：

  Mammalian ribonucleotide reductase, a chemotherapeutic target, has two subunits, mR1 and mR2, and is inhibited by AcF(1)TLDADF(7), denoted P7. P7 corresponds to the C-terminus of mR2 and competes with mR2 for binding to mR1. We report results of a structure-function analysis of P7, obtained using a new assay measuring peptide ligand binding to mR1, that demonstrate stringent specificity for Phe at F-7, high specificity for Phe at F-1, and little specificity for the N-acyl group. They support a structural model in which the dominant interactions of P7 occur at two mR1 sites, the F-1 and F-7 subsites. The model is constructed from the structure of Escherichia colt R1 (eR1) complexed with the C-terminal peptide from eR2, aligned sequences of mR1 and eR1, and the trNOE-derived structure of mR1-bound P7. Comparison of this model with similar models constructed for mR1 complexed with other inhibitory ligands indicates that increased F-1 subsite interaction can offset lower F-7 subsite interaction and suggests strategies for the design of new, higher affinity inhibitors.

  DOI：

  10.1021/jm000335r
• 作为产物：
  描述：

  DL-4-氯苯丙氨酸 生成 DL-4-chlorophenylalanine t-butyl ester
  参考文献：
  名称：

  Method of treating nausea and vomiting with certain

  摘要：

  一种治疗哺乳动物呕吐的方法，该方法包括给所述哺乳动物施用一种能减少大脑中5-羟色胺含量的化合物，以抑制呕吐；其中包括具有以下公式的化合物：##STR1## 其中，R选自氢、低级烷基、三氟甲基、羧基或低级烷氧基甲酸基；R1和R2是氢或低级烷基；Z是三氟甲基或卤素；其光学异构体和药用可接受盐；本发明的两个优选化合物是fenfluramine和norfenfluramine。

  公开号：

  US04857553A1

文献信息

• [EN] NEOSEPTINS: SMALL MOLECULE ADJUVANTS<br/>[FR] NÉOSEPTINES : PETITS ADJUVANTS MOLÉCULAIRES
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2014131023A1

  公开（公告）日：2014-08-28

  A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.

  揭示了一种MD-2:TLR4复合物激动剂化合物，其结构对应于所定义的公式（I）。还公开了其制备和使用方法，以及含有该化合物的药物组合物。
• Neutrophil inhibitors to reduce inflammatory response
  申请人：The Procter & Gamble Company

  公开号：US20040006104A1

  公开（公告）日：2004-01-08

  The invention provides novel compounds selected from the group consisting of: 1 The compounds of the present invention are useful for the treatment and prevention of a variety of diseases and conditions associated with undesirable or abnormal inflammatory responses, such as ischemia-reperfusion injury. Accordingly, the invention further provides pharmaceutical compositions comprising these compounds. The invention still further provides methods of treatment or prevention for the above disorders using theses compounds or the compositions containing them.

  该发明提供了从以下组合中选择的新化合物：1本发明的化合物对治疗和预防与不良或异常炎症反应相关的各种疾病和病况，如缺血再灌注损伤，具有益处。因此，该发明还提供了包括这些化合物的药物组合物。该发明还提供了使用这些化合物或含有它们的组合物进行上述疾病的治疗或预防的方法。
• Discovery and Structure–Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists
  作者：Matthew D. Morin、Ying Wang、Brian T. Jones、Lijing Su、Murali M. R. P. Surakattula、Michael Berger、Hua Huang、Elliot K. Beutler、Hong Zhang、Bruce Beutler、Dale L. Boger

  DOI：10.1021/acs.jmedchem.6b00177

  日期：2016.5.26

  Herein, we report studies leading to the discovery of the neoseptins and a comprehensive examination of the structure–activity relationships (SARs) of this new class of small-molecule mouse Toll-like receptor 4 (mTLR4) agonists. The compounds in this class, which emerged from screening an α-helix mimetic library, stimulate the immune response, act by a well-defined mechanism (mouse TLR4 agonist), are

  在本文中，我们报道了导致新肽段的发现以及对这种新型小分子小鼠Toll样受体4（mTLR4）激动剂的结构-活性关系（SAR）的全面研究的报告。该类化合物是通过筛选α-螺旋模拟物文库而产生的，可刺激免疫反应，并通过明确的机制发挥作用（小鼠TLR4激动剂），易于生产和结构操纵，具有精美的SAR，无毒，与脂多糖相比，即使它们共享相同的受体，也能引起改善的和质上不同的反应。
• NEOSEPTINS: SMALL MOLECULE ADJUVANTS
  申请人：THE SCRIPPS RESEARCH INSTITUTE

  公开号：US20160000907A1

  公开（公告）日：2016-01-07

  A MD-2:TLR4 complex agonist compound is disclosed whose structure corresponds to Formula (I), as defined within. Also disclosed are a method of its preparation and use, as well as a pharmaceutical composition containing the same.

  本文披露了一种结构符合公式（I）定义的MD-2：TLR4复合激动剂化合物。同时还披露了其制备和使用方法，以及含有该化合物的药物组合物。
• Angiotensin converting enzyme inhibitors
  申请人：UNIVERSITY OF MIAMI

  公开号：EP0036713A2

  公开（公告）日：1981-09-30

  Novel inhibitors of angiotensin converting enzyme having the general formula R-A-S-Z are disclosed as potent inhibitors of angiotensin converting enzyme and are useful anti-hypertensive agents.

  公开了通式为 R-A-S-Z 的新型血管紧张素转换酶抑制剂，它们是血管紧张素转换酶的强效抑制剂，也是有用的抗高血压药物。